



Antibodies

T7-529-T025

## Monoclonal Antibody to CD11c PE-Cy™7 conjugated (25 tests)

<b>Clone:</b>	BU15
<b>Isotype:</b>	Mouse IgG1
<b>Specificity:</b>	The antibody BU15 reacts with CD11c (alphaX, p150), a 150 kDa integrin expressed mainly on dendritic cells and tissue macrophages. HLDA III; WS Code M 256 HLDA V; WS Code AS S143 HLDA VI; WS Code AS Ref.6
<b>Regulatory Status:</b>	RUO
<b>Immunogen:</b>	Dendritic cells of synovial fluid
<b>Species Reactivity:</b>	Human, Monkey
<b>Preparation:</b>	The purified antibody is conjugated with tandem dye PE-Cy™7 under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
<b>Storage Buffer:</b>	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
<b>Storage / Stability:</b>	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
<b>Usage:</b>	The reagent is designed for Flow Cytometry analysis of human blood cells using 4 µl reagent / 100 µl of whole blood or 10 <sup>6</sup> cells in a suspension. The content of a vial (0.1 ml) is sufficient for 25 tests.
<b>Expiration:</b>	See vial label
<b>Lot Number:</b>	See vial label
<b>Background:</b>	CD11c (p150, alphaX integrin subunit) forms complex with CD18 (beta2 integrin subunit) and is expressed mainly on tissue macrophages and dendritic cells. CD11c binds to complement fragment iC3b, fibrinogen, VCAM-1 and ICAM-2 or e.g. CD90. Like other beta2 integrins, CD11c/CD18 plays roles in cell migration and phagocytosis. Moreover, interaction of CD11c/CD18 with plasminogen regulates plasmin activities, and interaction with heparin counteracts binding of iC3b.

**For laboratory research only, not for drug, diagnostic or other use.**

**Antibodies****References:**

- \*Sadhu C, Ting HJ, Lipsky B, Hensley K, Garcia-Martinez LF, Simon SI, Staunton DE: CD11c/CD18: novel ligands and a role in delayed-type hypersensitivity. *J Leukoc Biol.* 2007 Jun;81(6):1395-403.
- \*Bullard DC, Hu X, Adams JE, Schoeb TR, Barnum SR: p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. *Am J Pathol.* 2007 Jun;170(6):2001-8.
- \*Vorup-Jensen T, Chi L, Gjelstrup LC, Jensen UB, Jewett CA, Xie C, Shimaoka M, Linhardt RJ, Springer TA: Binding between the integrin alphaXbeta2 (CD11c/CD18) and heparin. *J Biol Chem.* 2007 Oct 19;282(42):30869-77.
- \*Gang J, Choi J, Lee JH, Nham SU: Identification of critical residues for plasminogen binding by the alphaXI-domain of the beta2 integrin, alphaXbeta2. *Mol Cells.* 2007 Oct 31;24(2):240-6.
- \*Hogg N, Takacs L, Palmer DG, Selvendran Y, Allen C: The p150,95 molecule is a marker of human mononuclear phagocytes: comparison with expression of class II molecules. *Eur J Immunol.* 1986 Mar;16(3):240-8.
- \*Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987).
- \*Trowald-Wigh G, Johannisson A, Hansson L: Canine neutrophil adhesion proteins and Fc-receptors in healthy dogs and dogs with adhesion protein deficiency, as studied by flow cytometry. *Vet Immunol Immunopathol.* 1993 Oct;38(3-4):297-310.
- \*Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995).
- \*Van der Vieren M, Le Trong H, Wood CL, Moore PF, St John T, Staunton DE, Gallatin WM: A novel leukointegrin, alpha d beta 2, binds preferentially to ICAM-3. *Immunity.* 1995 Dec;3(6):683-90.
- \*Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).
- \*Rezzonico R, Imbert V, Chicheportiche R, Dayer JM: Ligation of CD11b and CD11c beta(2) integrins by antibodies or soluble CD23 induces macrophage inflammatory protein 1alpha (MIP-1alpha) and MIP-1beta production in primary human monocytes through a pathway dependent on nuclear factor-kappaB. *Blood.* 2001 May 15;97(10):2932-40.
- \*Myou S, Zhu X, Boetticher E, Qin Y, Myo S, Meliton A, Lambertino A, Munoz NM, Hamann KJ, Leff AR: Regulation of adhesion of AML14.3D10 cells by surface clustering of beta2-integrin caused by ERK-independent activation of cPLA2. *Immunology.* 2002 Sep;107(1):77-85.
- \*Sadhu C, Hendrickson L, Dick KO, Potter TG, Staunton DE: Novel Tools for Functional Analysis of CD11c: Activation-Specific, Activation-Independent, and Activating Antibodies. *J Immunoassay Immunochem.* 2008;29(1):42-57.
- \*Angel CE, Lala A, Chen CJ, Edgar SG, Ostrovsky LL, Dunbar PR: CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. *Int Immunol.* 2007 Nov;19(11):1271-9.
- \*And many other.

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at [www.exbio.cz](http://www.exbio.cz).

Cy™ and CyDye™ are registered trademarks of GE Healthcare.

**For laboratory research only, not for drug, diagnostic or other use.**

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic  
Tel: +420 261 090 666 | Fax: +420 261 090 660 | [orders@exbio.cz](mailto:orders@exbio.cz) | [www.exbio.cz](http://www.exbio.cz)